ArticleMolecular biology reports2026
Therapeutic modulation of inflammation and oxidative stress in rheumatoid arthritis through Choerospondias axillaris intervention: evidence from in-vitro and in-vivo studies.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder, and current therapeutic approaches often present adverse effects on human health. This highlights the need to explore dietary sources of bioactive compounds for RA management. This study aimed to evaluate the potential of a Choerospondias axillaris (C. axillaris) chewable nutraceutical tablet (LT), formulated from the underutilized fruit of C. axillaris, for RA management.
methodsLTs were prepared by direct compression using C. axillaris fruit powder as the principal ingredient. The tablets were characterized using Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and energy-dispersive X-ray spectroscopy (EDX). Antioxidant activity was evaluated using the DPPH free-radical scavenging assay. Potential RA-associated targets of C. axillaris were predicted using PharmMapper, followed by Cytoscape-based network analysis and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Selected targets were evaluated in synovial fibroblasts using quantitative PCR (qPCR) and in a collagen-induced arthritis (CIA) rat model. Molecular docking was performed to assess interactions between major bioactive compounds and selected RA-related proteins.
resultsThe formulated tablets contained detectable mineral elements and phytochemical constituents. Network pharmacology identified 20 potential targets associated with C. axillaris activity against RA. Molecular docking revealed potential interactions between selected bioactive compounds and key RA-related proteins. In vitro treatment reduced MAPK14, MMP9, and IL2 expression in synovial fibroblasts. In vivo treatment also suppressed inflammatory responses in the plasma of CIA rats.
conclusionsThese findings indicate that C. axillaris bioactive compounds may modulate molecular targets associated with RA-related inflammation. The findings support further investigation of C. axillaris-derived nutraceutical formulations for RA management.
Indexed as
Identifiers
42905313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.